Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 2,901,816 7.000% |
819,693 (+39.37%) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | Merus N.V. MRUS |
Commodore Capital LP | 4,747,373 8.200% |
2,014,806 (+73.73%) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | SAB Biotherapeutics, Inc. SABS |
Commodore Capital LP | 1,831,746 3.500% |
1,831,746 (New Position) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Commodore Capital LP | 1,924,074 3.700% |
552,735 (+40.31%) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-06-14 | 13G | Vera Therapeutics, Inc. VERA |
Commodore Capital LP | 5,001,783 11.300% |
2,658,926 (+113.49%) |
Filing History |
| 2024-01-19 4:05 pm Purchase |
2024-01-10 | 13G | Adicet Bio, Inc. ACET |
Commodore Capital LP | 4,250,000 9.800% |
4,250,000 (New Position) |
Filing History |
| 2023-12-22 4:05 pm Purchase |
2023-12-14 | 13G | C4 Therapeutics, Inc. CCCC |
Commodore Capital LP | 3,800,000 7.700% |
3,800,000 (New Position) |
Filing History |
| 2023-12-01 4:15 pm Purchase |
2023-11-24 | 13G | Spyre Therapeutics, Inc. SYRE |
Commodore Capital LP | 1,834,084 6.100% |
1,834,084 (New Position) |
Filing History |
| 2023-11-03 4:05 pm Purchase |
2023-10-25 | 13G | Harpoon Therapeutics, Inc. HARP |
Commodore Capital LP | 1,703,465 9.900% |
1,703,465 (New Position) |
Filing History |
| 2023-10-27 4:05 pm Purchase |
2023-10-19 | 13G | Nkarta, Inc. NKTX |
Commodore Capital LP | 2,730,000 5.600% |
2,730,000 (New Position) |
Filing History |
| 2023-10-16 4:05 pm Purchase |
2023-10-04 | 13G | SAB Biotherapeutics, Inc. SABS |
Commodore Capital LP | 693,246 9.900% |
693,246 (New Position) |
Filing History |
| 2023-10-12 4:05 pm Purchase |
2023-10-02 | 13G | Soleno Therapeutics, Inc. SLNO |
Commodore Capital LP | 885,741 6.000% |
885,741 (New Position) |
Filing History |
| 2023-10-06 4:05 pm Purchase |
2023-10-04 | 13G | VistaGen Therapeutics, Inc. VTGN |
Commodore Capital LP | 2,367,884 9.900% |
792,884 (+50.34%) |
Filing History |
| 2023-08-09 4:15 pm Purchase |
2023-08-07 | 13G | VistaGen Therapeutics, Inc. VTGN |
Commodore Capital LP | 1,575,000 19.700% |
1,575,000 (New Position) |
Filing History |
| 2023-04-27 4:05 pm Sale |
2023-04-24 | 13G | Ambrx Biopharma Inc. AMAM |
Commodore Capital LP | 31,181,983 8.100% |
-4,518,017 (-12.66%) |
Filing History |
| 2023-04-24 4:05 pm Purchase |
2023-04-14 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 2,082,123 5.100% |
633,483 (+43.73%) |
Filing History |
| 2023-04-20 4:05 pm Purchase |
2023-04-10 | 13G | Adverum Biotechnologies, Inc. ADVM |
Commodore Capital LP | 615,814 6.100% |
615,814 (New Position) |
Filing History |
| 2023-03-30 4:05 pm Purchase |
2023-03-20 | 13G | BELLUS Health Inc. BLU |
Commodore Capital LP | 6,579,359 5.200% |
1,275,802 (+24.06%) |
Filing History |
| 2023-03-03 4:10 pm Purchase |
2023-02-23 | 13G | Ambrx Biopharma Inc. AMAM |
Commodore Capital LP | 35,700,000 13.200% |
9,450,000 (+36.00%) |
Filing History |
| 2023-03-03 4:05 pm Purchase |
2023-02-21 | 13G | Ambrx Biopharma Inc. AMAM |
Commodore Capital LP | 26,250,000 9.700% |
26,250,000 (New Position) |
Filing History |